{"id":"adezunap-ap707","safety":{"commonSideEffects":[{"rate":null,"effect":"Lymphopenia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting adenosine deaminase (ADA), adezunap causes accumulation of adenosine and deoxyadenosine, which are toxic to lymphocytes and promote their selective elimination. This mechanism is intended to reduce pathogenic immune responses in autoimmune and inflammatory conditions. The drug targets the purine metabolism pathway to achieve immunosuppressive effects.","oneSentence":"Adezunap is a small-molecule inhibitor of adenosine deaminase that increases intracellular adenosine and deoxyadenosine levels to promote immune cell apoptosis and reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:48.544Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune hepatitis"},{"name":"Primary biliary cholangitis"}]},"trialDetails":[{"nctId":"NCT06072573","phase":"PHASE3","title":"Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy","status":"UNKNOWN","sponsor":"Apurano Pharmaceuticals GmbH","startDate":"2023-11-02","conditions":"Pain, Pain Syndrome, Pain, Chronic","enrollment":558},{"nctId":"NCT06071962","phase":"PHASE3","title":"Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain","status":"UNKNOWN","sponsor":"Apurano Pharmaceuticals GmbH","startDate":"2023-11-02","conditions":"Pain, Pain Syndrome, Pain, Chronic","enrollment":558},{"nctId":"NCT06072001","phase":"PHASE3","title":"Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis","status":"UNKNOWN","sponsor":"Apurano Pharmaceuticals GmbH","startDate":"2023-11-02","conditions":"Pain, Pain Syndrome, Pain, Chronic","enrollment":558},{"nctId":"NCT06071949","phase":"PHASE3","title":"Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis","status":"UNKNOWN","sponsor":"Apurano Pharmaceuticals GmbH","startDate":"2023-11-02","conditions":"Pain, Pain Syndrome, Pain, Chronic","enrollment":558},{"nctId":"NCT06071988","phase":"PHASE3","title":"Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Apurano Pharmaceuticals GmbH","startDate":"2023-11-02","conditions":"Pain, Pain Syndrome, Pain, Chronic","enrollment":558},{"nctId":"NCT06071975","phase":"PHASE3","title":"Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy","status":"UNKNOWN","sponsor":"Apurano Pharmaceuticals GmbH","startDate":"2023-11-02","conditions":"Pain, Pain Syndrome, Pain, Chronic","enrollment":558},{"nctId":"NCT06072560","phase":"PHASE3","title":"Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain","status":"UNKNOWN","sponsor":"Apurano Pharmaceuticals GmbH","startDate":"2023-11-02","conditions":"Pain, Pain Syndrome, Pain, Chronic","enrollment":558},{"nctId":"NCT06071936","phase":"PHASE3","title":"Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Apurano Pharmaceuticals GmbH","startDate":"2023-11-02","conditions":"Pain, Pain Syndrome, Pain, Chronic","enrollment":558}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Adezunap (AP707)","genericName":"Adezunap (AP707)","companyName":"Apurano Pharmaceuticals GmbH","companyId":"apurano-pharmaceuticals-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adezunap (AP707) is being studied for its efficacy and tolerability in patients with chronic pain due to diabetic polyneuropathy. Clinical trials are investigating Adezunap for conditions including pain, chronic pain, and chronic pain syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}